Molecular Oncology Q1
Unclaimed
Molecular Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Genetics with an H index of 113. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on cancer, molecular biology, molecular genetics. It has an SJR impact factor of 1,94 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,94.
Molecular Oncology focuses its scope in these topics and keywords: cancer, carcinoma, breast, gene, lymphoma, hormonedependent, induced, ischemic, hodgkin, hormonenaive, ...
Type: Journal
Type of Copyright: CC BY
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
2700 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
1,94
SJR Impact factor113
H Index203
Total Docs (Last Year)659
Total Docs (3 years)10551
Total Refs4100
Total Cites (3 years)641
Citable Docs (3 years)5.42
Cites/Doc (2 years)51.98
Ref/DocOther journals with similar parameters
Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1
Compare this journals
Aims and Scope
Best articles by citations
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
View moreSNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer
View moreIdentification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)
View moreQuantifying initial cellular events of mouse radiation lymphomagenesis and its tumor prevention in vivo by positron emission tomography and magnetic resonance imaging
View moreIL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma
View moreTumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells
View moreCorrigendum to "Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III" [Mol. Oncol. 8 (2) (2014) 417-30]
View moreUse of high density antibody arrays to validate and discover cancer serum biomarkers
View moreExpression and hypoxic up-regulation of neuroglobin in human glioblastoma cells
View moreCirculating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer
View moreTargeted polytherapy in small cell sarcoma and its association with doxorubicin
View moreSMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-beta signaling promotes prostate cancer bone metastasis
View moreNanoparticle mediated silencing of DNA repair sensitizes pediatric brain tumor cells to gamma-irradiation
View moreFibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors
View moreRhoC and ROCKs regulate cancer cell interactions with endothelial cells
View morePatient advocacy groups: Empowering patients in their fight against cancer
View moreHas the US Cancer Centre model been 'successful'? Lessons for the European cancer community
View moreMicrosatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study
View moreComparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer
View moreTRIM8 regulates stemness in glioblastoma through PIAS3-STAT3
View moreZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation
View moreOncolytic vaccinia virus synergizes with irinotecan in colorectal cancer
View moreNemosis of fibroblasts is inhibited by benign HaCaT keratinocytes but promoted by malignant HaCaT cells
View moreOn the Horizon: Europe's next round of science funding
View more
Comments